Zinc as an adjunct therapy in the management of severe pneumonia among Gambian children: randomized controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were infants, young children and children, both men and women.

Six hundred and four children 2-59 months of age presenting with severe pneumonia at six urban and rural health care facilities in The Gambia were individually randomised to receive placebo (n = 301) or zinc (n = 303) for seven days.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

The subject headings attached to it are Gambia, Pneumonia and Zinc.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Journal of global health), a journal based in Scotland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.